ERO1L Is a Novel and Potential Biomarker in Lung Adenocarcinoma and Shapes the Immune-Suppressive Tumor Microenvironment.

Lihui Liu,Chao Wang,Sini Li,Yan Qu,Pei Xue,Zixiao Ma,Xue Zhang,Hua Bai,Jie Wang

Frontiers in immunology（2021）

引用 12|浏览7

暂无评分

摘要

This study found that overexpression of was associated with poor prognoses in patients with LUAD. Overexpression of was indicative of a hypoxia-induced immune-suppressive TIME, which was shown to confer resistance to immunotherapy in patients with LUAD. Further studies are required to assess the potential role of as a biomarker for immunotherapy efficacy in LUAD.

查看译文

关键词

ERO1L,biomarker,immunotherapy,lung adenocarcinoma,tumor microenvironment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要